Corcept Therapeutics Inc. (CORT) Financials
Key financial figures for Corcept Therapeutics Inc. (Q2 2026).
Corcept Therapeutics Incorporated reported revenue of $256.1 million for Q2 FY2026, up 31.7% from the same period a year earlier. Net income was $42.1 million, or $0.36 per share. Operating margin came to 16.12%, against 13.72% a year earlier. Free cash flow for the period was $31.0 million. Across the last 5 reported quarters, quarterly revenue has risen from $194.4 million in Q2 FY2025 to $256.1 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Corcept Therapeutics Incorporated are on the SentiSense financials page.
- Revenue
- $256M
- Net Income
- $42M
- EPS
- $0.40
- Total Assets
- $889M
- Operating Cash Flow
- $34M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $256M | $42M | $0.36 | 16.12% | $31M |
| Q1 FY2026 | $165M | -$31M | -$0.30 | -30.08% | -$17M |
| Q4 FY2025 | $202M | $24M | $0.20 | 2.22% | $38M |
| Q3 FY2025 | $208M | $20M | $0.16 | 4.92% | $54M |
| Q2 FY2025 | $194M | $35M | $0.29 | 13.72% | $44M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $761M | $100M | $0.82 | 5.88% | $142M |
| FY2024 | $675M | $140M | $1.23 | 20.29% | $196M |
| FY2023 | $482M | $106M | $0.94 | 22.24% | $127M |
Frequently asked questions
What was Corcept Therapeutics Incorporated's revenue last quarter?
Corcept Therapeutics Incorporated reported revenue of $256.1 million for Q2 FY2026, up 31.7% from the same period a year earlier.
Is Corcept Therapeutics Incorporated profitable?
Yes. Corcept Therapeutics Incorporated reported net income of $42.1 million for Q2 FY2026, a net margin of 16.45% on revenue.
How has Corcept Therapeutics Incorporated's margin trended?
Operating margin was 16.12% in Q2 FY2026, compared with 13.72% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Corcept Therapeutics Incorporated generate?
Corcept Therapeutics Incorporated generated free cash flow of $31.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Corcept Therapeutics Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.